FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020766596> ?p ?o ?g. }

• W2020766596 endingPage "1726" @default.
• W2020766596 startingPage "1723" @default.
• W2020766596 abstract "HomeStrokeVol. 33, No. 6Warfarin-Aspirin Recurrent Stroke Study (WARSS) Trial Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBWarfarin-Aspirin Recurrent Stroke Study (WARSS) TrialIs Warfarin Really a Reasonable Therapeutic Alternative to Aspirin for Preventing Recurrent Noncardioembolic Ischemic Stroke? Graeme J. Hankey, MBBS, MD, FRCP, FRCP(Edin), FRACP Graeme J. HankeyGraeme J. Hankey From the Department of Neurology, Royal Perth Hospital, Perth, Western Australia. Search for more papers by this author Originally published1 Jun 2002https://doi.org/10.1161/01.STR.0000016922.22707.27Stroke. 2002;33:1723–1726Eleven years ago, on June 1, 1991, Dr J.P. Mohr addressed delegates of the International Conference on Stroke, Geneva, about anticoagulants as a therapeutic strategy in stroke. He bemoaned the fact that heparin and warfarin had the “bad luck” to be manufactured initially in the post-World War II period, before drugs were evaluated by controlled clinical trials. As a consequence, clinicians judged their effectiveness on the basis of theory and compared their personal experience with historical controls and with those found in the literature. With the passage of time, the drug patents expired, the views and practices of clinicians became polarized, and any commercial and scientific motive to conduct controlled clinical trials of anticoagulation in secondary stroke prevention, once called for, disappeared. Dr Mohr sadly concluded that “there are no [reliable] data really” for anticoagulation after ischemic stroke. This was probably the platform from which he planned, with colleagues, the Warfarin-Aspirin Recurrent Stroke Study (WARSS).1What Was the Rationale for Comparing the Effectiveness of Warfarin and Aspirin in Noncardioembolic Ischemic Stroke?Noncardioembolic ischemic stroke underpins ≈60% of all first-ever and recurrent strokes. The major causes are (1) thrombotic occlusion of large and medium-sized arteries that is due to in situ atherothrombosis or atherothromboembolism and (2) thrombotic occlusion of small perforating intracerebral arteries affected by microatheroma/lipohyalinosis.The formation of thrombus on the subendothelial tissue of arteries depends on the initial formation of a platelet plug (by means of platelet adhesion, activation, and aggregation) and the generation of a meshwork of fibrin (by means of the coagulation cascade). Antiplatelet drugs are designed to prevent the formation of the “white” platelet plug, and anticoagulants are designed to prevent the formation of the “red” fibrin clot. Theoretically, antiplatelet and anticoagulant therapy should be effective in preventing recurrent noncardioembolic stroke, provided that they can both be administered safely over a long period of time.What Was the Previous Evidence for the Effectiveness of Warfarin and Aspirin in Noncardioembolic Ischemic Stroke?Indirect Comparisons of Effectiveness Compared With ControlA systematic review of 11 randomized controlled trials (RCTs) of aspirin versus control in ≈10 000 patients with previous stroke or transient ischemic attack (TIA) revealed that long-term aspirin therapy reduced the relative risk of recurrent serious vascular events (stroke, myocardial infarction [MI], or death due to a vascular cause) by 13% (95% CI 6% to 19%), corresponding to an absolute risk reduction of ≈1% per year (ie, from 7% to 6% per year).2,3A systematic review of 9 RCTs of anticoagulation versus control in 1214 patients with previous stroke or TIA showed that long-term oral anticoagulation was associated with no significant reduction in the rate of serious vascular events during follow-up (odds ratio [OR] 0.96, 95% CI 0.68 to 1.37). However, oral anticoagulation was associated with a trend toward a reduction in recurrent ischemic/unknown stroke (OR 0.79, 95% CI 0.56 to 1.13) but at the expense of an increase in fatal symptomatic hemorrhagic stroke (OR 2.54, 95% CI 1.19 to 5.45), thus nullifying any overall effect on recurrent stroke of all types (ischemic and hemorrhagic) during follow-up (OR 0.92, 95% CI 0.67 to 1.27).4Direct “Head-to-Head” ComparisonsA systematic review of 4 RCTs of oral anticoagulants versus antiplatelet therapy in a total of 1870 patients with previous TIA or minor stroke of presumed arterial origin showed that compared with antiplatelet therapy, long-term oral anticoagulant therapy with a high international normalized ratio (INR, 3.0 to 4.5) was associated with a significantly higher rate of recurrent serious vascular events in the 1316 patients randomized (OR 2.38, 95% CI 1.63 to 3.48).5 This was mainly because of a higher rate of major bleeding complications (OR 5.42, 95% CI 3.21 to 9.13) and recurrent stroke of any type (OR 2.06, 95% CI 1.22 to 3.45).5 However, there was no difference in the rate of recurrent ischemic stroke (OR 1.02, 95% CI 0.48 to 2.16).5Among the 493 patients randomized to long-term oral anticoagulant therapy with a medium INR (2.1 to 3.6) or antiplatelet therapy, there was no difference in the rate of recurrent ischemic stroke (OR 0.96, 95% CI 0.36 to 2.54), recurrent stroke of any type (OR 0.81, 95% CI 0.35 to 1.87), recurrent stroke or vascular death (relative risk 1.07, 95% CI 0.54 to 2.12), or the rate of major bleeding complications (OR 1.21, 95% CI 0.56 to 2.59).5What Was the Unresolved Burning Question?Given that antiplatelet therapy was the antithrombotic treatment of first choice for the prevention of recurrent serious vascular events in patients with previous noncardioembolic TIA or ischemic stroke,3 the unresolved burning question asked by the WARSS investigators was whether low- or medium-intensity oral anticoagulation was more effective than (ie, superior to) antiplatelet therapy (the gold standard). It was not whether anticoagulation was equivalent to antiplatelet therapy, presumably because anticoagulation would not be accepted into clinical practice (even if proven equivalent to antiplatelet therapy) because of greater bleeding risks and the inconvenience and cost associated with repeated blood INR rests.Four randomized trials have now set out to address this question: the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT), 6 the Warfarin-Aspirin Symptomatic Intracranial Disease Study (WASID),7,8 and the Aortic Arch Related Cerebral Hazard (ARCH) trial (principal investigators G.A. Donnan and P. Amarenco), which are still ongoing, and WARSS, which is now reported.1What Are the Strengths of WARSS?The strengths of WARSS, for which the investigators are to be congratulated, are that it is by far the largest-ever randomized trial of oral anticoagulant therapy (low-medium INR) versus antiplatelet therapy, increasing the evidence base by ≈450% (ie, from 493 patients to 2699 patients). Moreover, the patients, attending clinicians, and outcome evaluators were all blinded to knowledge of the treatment allocation (ie, it was a double-blind study), which is a remarkable effort for a study in which the effect of 1 intervention (warfarin) needs to be monitored by frequent blood (INR) tests. Furthermore, the daily INR values were maintained within the target range (1.4 to 2.8) in 71% of the patients; follow-up at 2 years was complete for 98.5% of the patients; and the etiologic subtype of the index ischemic stroke was identified, allowing for an analysis of the consistency of the overall treatment effects in etiologic subtypes of stroke.What Are the Weaknesses of WARSS?The main weaknesses of WARSS, in my opinion, relate to the choice of the INR range (1.4 to 2.8) for patients allocated warfarin, the choice of the primary outcome event, and the estimated likely treatment effect to reject the null hypothesis.The lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation is an INR of ≈1.8.9 Patients with an INR of 1.7 have twice (95% CI 1.6 to 2.4) the odds of stroke as those with an INR of 2.0, and patients with an INR of 1.5 have a 3.3 (2.4 to 4.6) times the odds of stroke as those with an INR of 2.0.9 If the same applies to patients with TIA/ischemic stroke due to arterial disease (which appears to be the case10), then an acceptable target INR as low as 1.4 is likely to be ineffective. Any possible favorable or unfavorable treatment effects of warfarin are likely to be underestimated in WARSS because the median daily INR for patients taking warfarin was only 1.9 and because 16.3% of the daily INR values were <1.4.The primary outcome event (recurrent ischemic stroke or death) was biased toward efficacy rather than efficacy and safety and should have included all the possible important benefits and hazards of warfarin and aspirin. These are nonfatal intracranial hemorrhage at the very least (so that the primary outcome would be recurrent stroke or death), nonfatal extracranial major hemorrhage as well, and also, ideally, nonfatal MI (ie, with the primary outcome event being nonfatal stroke, nonfatal MI, nonfatal extracranial major hemorrhage, or death). The rationale for including nonfatal MI would be to determine whether the proven additional benefits of antiplatelet therapy in preventing MI among stroke patients could be matched, or exceeded, by warfarin.The WARSS study was powered to detect a 30% relative reduction in the primary outcome event rate for 1 therapy from 16% at 2 years (to 11.2% at 2 years) with 80% power and a 5% two-sided probability of a type I error. From the available evidence before the trial was terminated,2–5 this was an overoptimistic estimate of the likely treatment effect. Consequently, the trial was underpowered statistically to reliably detect or exclude more modest, but clinically realistic and important, treatment effects.How Should the Results of WARSS Be Interpreted?The results of WARSS can be interpreted in several different ways, as discussed below.Warfarin Is Equally Effective as AspirinThe WARSS investigators interpreted their failure to reject the null hypothesis (eg, no significant difference in effectiveness between warfarin and aspirin) as indicating that “both warfarin and aspirin [can be regarded] as reasonable therapeutic alternatives.”1 However, failure to reject the null hypothesis is not proof of the null hypothesis or of equivalence. It may simply be the result of inadequate sample size to reliably detect, with 95% confidence, up to a 38% excess hazard of the primary outcome event for warfarin compared with aspirin or up to an 8% excess hazard of the primary outcome event for aspirin compared with warfarin.WARSS was neither designed nor powered to study equivalence. Equivalence trials set out to prove that treatments are not different. The null hypothesis to be tested (and disproved if the trial shows equivalence) is actually that the treatments are different.11 When an equivalence trial is designed, a power calculation and sample size determination are performed to assess the probability that a lack of difference would be obtained by chance. Although proof of exact equality is not possible, this issue is resolved in practice by defining an arbitrary practical equivalence margin, called the noninferiority margin.11 To detect this difference, on average, equivalence trials, compared with conventional superiority trials (eg, WARSS), usually require a 10% larger sample size. The null hypothesis is rejected if the upper limit of the CI for the difference between the treatments is smaller than this predefined margin.11Warfarin Is a Potentially Hazardous PlaceboAnother interpretation of the results of WARSS is that the effect of warfarin was equivalent to that of a placebo. This is based on an indirect comparison of the 13% (95% CI −8% to 38%) excess relative hazard (11.25% excess relative risk) of recurrent ischemic stroke or death among the WARSS patients randomized to warfarin, as opposed to aspirin,1 with the 13% (95% CI 6% to 19%) excess relative risk of serious vascular events among the 10 000 TIA/ischemic stroke patients randomized to placebo, as opposed to aspirin, in the 11 RCTs reviewed by Algra and van Gijn.2 However, this indirect comparison is potentially flawed because it compares slightly different estimates (relative risks versus relative hazards) of slightly different outcome events against the same control (aspirin), not each other. Such indirect comparisons are not reliable, in the same way that it is unreliable to compare the United States and Canadian ice hockey teams by their respective performances against the Russian team; it is more reliable to have them oppose each other directly.Warfarin Is Not More Effective Than AspirinThe WARSS investigators aimed to determine whether warfarin would prove to be superior to aspirin in the prevention of recurrent ischemic stroke in patients with a prior noncardioembolic ischemic stroke. They failed, and therefore failed to reject the null hypothesis.I believe that the correct interpretation of the results of WARSS is that warfarin was not proven to be superior to aspirin. It is correct to say, with 95% confidence, that warfarin may be up to 8% more effective than aspirin, and it may be up to 38% less effective. More trials are needed to refine these estimates.What Are the Implications of WARSS for Clinical Practice?The results of WARSS can be generalized only to the type of patients randomized in WARSS (ie, patients with recent noncardioembolic ischemic stroke who do not have high-grade symptomatic carotid stenosis or a contraindication to warfarin therapy) who are followed up and managed in a similar manner.For these patients, warfarin should probably be used only in the context of an RCT or perhaps if the patient is allergic to, is intolerant of, or has failed effective antiplatelet therapies (eg, aspirin, clopidogrel, or dipyridamole therapy) in isolation and combination, until the results of ongoing clinical trials (eg, ESPRIT, WASID, and ARCH) are known.What Are the Implications of WARSS for Research?WARSS TrialIt is possible that the WARSS trial failed to detect a favorable overall treatment effect of warfarin compared with aspirin (up to 8% less hazard of the primary outcome event) because of a lack of statistical power. In addition, such a favorable treatment effect may even be >8% if warfarin is used at a higher INR of ≈2.0 to 3.0 (ESPRIT, WASID, and ARCH trials) and is used in patients with specific etiologic subtypes of ischemic stroke, such as those with aortic arch atherothromboembolism (ARCH trial), intracranial large-artery atherosclerosis (WASID trial), and the antiphospholipid antibody syndrome (Antiphospholipid Antibody Stroke Study).12 Finally, evaluating effectiveness by means of a more composite primary outcome event, which includes nonfatal intracranial and extracranial hemorrhage and MI, will not only yield more statistical power but may also provide a better perspective of the overall relative efficacy and safety of warfarin and antiplatelet therapies.Ongoing Clinical TrialsESPRIT TrialThe ESPRIT trial is a randomized single-blind trial that aims (in 1 arm of the trial) to compare the efficacy and safety of warfarin (INR 2.0 to 3.0) versus aspirin (in any dose between 30 and 325 mg daily) in patients after cerebral ischemia due to presumed arterial causes (see online discussion at http://home.wxs.nl/≈esprit).6 Treatment allocation is random and open, but assessment of outcome is blind to the treatment allocation. The primary outcome is the composite event: “ death from all vascular causes, nonfatal stroke, nonfatal myocardial infarction, or major bleeding complication.”6 As of March 4, 2002, ≈800 of a planned 3000 patients have been randomized to warfarin versus aspirin (Ale Algra, MD, written communication, March 2002).WASID TrialThe WASID trial is a randomized double-blind clinical trial that aims (1) to examine whether warfarin (INR 2.0 to 3.0) or aspirin (1300 mg/d) is more effective for preventing stroke (ischemic or hemorrhagic) and vascular death in patients with symptomatic stenosis (50% to 99%) of a major intracranial artery and (2) to identify patients whose rate of ischemic stroke in the territory of the stenotic intracranial artery is sufficiently high to justify a subsequent trial comparing intracranial angioplasty/stenting with the best medical therapy in these patients.7,8 The WASID trial began enrolling patients in February 1999, with a goal of enrolling 806 patients at 60 sites in the United States and Canada over 3 years.ARCH TrialThe ARCH trial is an open RCT to test the null hypothesis that warfarin (INR 2.0 to 3.0) or clopidogrel (75 mg/d) plus aspirin (75 to 325 mg/d) in patients with a prior ischemic stroke or peripheral embolism associated with proximal aortic plaque with complex (≥4-mm-thick and/or mobile) features is equally effective in preventing subsequent stroke or vascular events. All outcome events will be reviewed by an Endpoint Committee which is blinded to treatment allocation. A total of 1500 patients will be recruited and followed for 5 years.FootnotesCorrespondence to Clinical Prof Graeme J. Hankey, Consultant Neurologist and Head of Stroke Unit, Department of Neurology, Royal Perth Hospital, Wellington Street, Perth, Western Australia 6001. E-mail [email protected] References 1 Mohr J, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, et al, for the Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001; 345: 1444–1451.CrossrefMedlineGoogle Scholar2 Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry. 1999; 66: 255.Letter.CrossrefGoogle Scholar3 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71–86.CrossrefMedlineGoogle Scholar4 Liu M, Counsell C, Sandercock P. Anticoagulants for preventing recurrence following ischaemic stroke or transient ischaemic attack (Cochrane Review).In: The Cochrane Library, Issue 1. Oxford, UK: Update Software; 2002.Google Scholar5 Algra A, De Schryver ELLM, van Gijn J, Kappelle LJ, Koudstaal PJ. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin (Cochrane Review).In: The Cochrane Library, Issue 1. Oxford, UK: Update Software; 2002.Google Scholar6 De Schryver ELLM, on behalf of the European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) Group. Design of ESPRIT: an international randomised trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. Cerebrovasc Dis. 2000; 10: 147–150.CrossrefMedlineGoogle Scholar7 Howlett-Smith HA, Cruz-Flores S, Belden JR, Sauerbeck LR, Levine RL, Stern BJ, Chimowitz MI, and the WASID Study Group. Management of intracranial arterial stenosis in a heterogeneous population. Neurology. 1998; 50: A295–A296.Google Scholar8 Benesch CG, Chimowitz MI, for the WASID investigators. Best treatment for intracranial arterial stenosis?: 50 years of uncertainty. Neurology. 2000; 55: 465–466.CrossrefMedlineGoogle Scholar9 Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. N Engl J Med. 1996; 335: 540–546.CrossrefMedlineGoogle Scholar10 Torn M, Algra A, Rosendaal FR. Oral anticoagulation for cerebral ischemia of presumed arterial origin. High initial bleeding risk. Neurology. 2001; 57: 1993–1999.CrossrefMedlineGoogle Scholar11 Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments, 1: ethical and scientific issues. Ann Intern Med. 2000; 133: 455–463.CrossrefMedlineGoogle Scholar12 Brey RL, Levine SR, Thompson JLP, Sacco RL, Tilley BC, Costigan TM, Rhine CB, Zidel A, Ruzicka J, Xu D, et al. Baseline frequencies, isotypes, and titers of antiphospholipid antibodies in the Warfarin Aspirin Recurrent Stroke Study/Antiphospholipid Antibody Study (WARSS/APASS) collaboration: preliminary results. Stroke. 2000; 31: 280.Abstract.Google Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Tsioufis C (2020) Ischemic stroke in atrial fibrillation patients: don't put the blame always on heart, Hellenic Journal of Cardiology, 10.1016/j.hjc.2018.07.003, 61:3, (208-209), Online publication date: 1-May-2020. Grifoni E, Giglio D, Guazzini G, Cosentino E, Latini E, Dei A, Del Rosso A, Guarnaccia V, Baldini M, Bartolozzi M, Martinucci P, Sani F, Giordano A, Dainelli F, Maggi F, Giulietti C, Romagnoli M, Cinotti S, Schipani E, Murgida G, Di Martino S, Cozzi A, Carli Ballola A, Dacomo D, Valori D and Masotti L (2019) Age-related burden and characteristics of embolic stroke of undetermined source in the real world clinical practice, Journal of Thrombosis and Thrombolysis, 10.1007/s11239-019-01951-5, 49:1, (75-85), Online publication date: 1-Jan-2020. Merbach D, Lawrence E, Mallick D and Marsh E (2019) A Therapeutic International Normalized Ratio Results in Smaller Infarcts and Better Outcomes for Patients with Ischemic Stroke, Journal of Stroke and Cerebrovascular Diseases, 10.1016/j.jstrokecerebrovasdis.2019.06.036, 28:10, (104278), Online publication date: 1-Oct-2019. Nam K, Kwon H, Kim H and Lee Y (2019) Left ventricular ejection fraction is associated with small vessel disease in ischaemic stroke patients, European Journal of Neurology, 10.1111/ene.13883, 26:5, (747-753), Online publication date: 1-May-2019. Katsi V, Georgiopoulos G, Skafida A, Oikonomou D, Klettas D, Vemmos K and Tousoulis D (2018) Noncardioembolic Stroke in Patients with Atrial Fibrillation, Angiology, 10.1177/0003319718791711, 70:4, (299-304), Online publication date: 1-Apr-2019. Rodríguez Lucci F and Ameriso S (2018) Accidente cerebrovascular embólico de origen indeterminado. El concepto ESUS, Neurología Argentina, 10.1016/j.neuarg.2017.11.004, 10:2, (98-102), Online publication date: 1-Apr-2018. Bhaskar S, Cordato D, Cappelen-Smith C, Cheung A, Ledingham D, Celermajer D and Levi C (2017) Clarion call for histopathological clot analysis in “cryptogenic” ischemic stroke: implications for diagnosis and treatment, Annals of Clinical and Translational Neurology, 10.1002/acn3.500, 4:12, (926-930), Online publication date: 1-Dec-2017. Sahay S, Nombela-Franco L, Rodes-Cabau J, Jimenez-Quevedo P, Salinas P, Biagioni C, Nuñez-Gil I, Gonzalo N, de Agustín J, del Trigo M, Perez de Isla L, Fernández-Ortiz A, Escaned J and Macaya C (2016) Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials, Heart, 10.1136/heartjnl-2016-309782, 103:2, (139-147), Online publication date: 15-Jan-2017. Manaktala R and Kluger J (2017) Role of Antiplatelet Therapy in Stroke Prevention in Patients With Atrial Fibrillation, Journal of Osteopathic Medicine, 10.7556/jaoa.2017.148, 117:12, (761-771), Online publication date: 1-Dec-2017., Online publication date: 1-Dec-2017. Chatterjee A and Derdeyn C (2015) Stenting in Intracranial Stenosis: Current Controversies and Future Directions, Current Atherosclerosis Reports, 10.1007/s11883-015-0527-4, 17:8, Online publication date: 1-Aug-2015. Thomson R and Anderson D (2013) Aspirin and Clopidogrel for Prevention of Ischemic Stroke, Current Neurology and Neuroscience Reports, 10.1007/s11910-012-0327-y, 13:2, Online publication date: 1-Feb-2013. Liberman A and Prabhakaran S (2013) Cryptogenic Stroke: How to Define It? How to Treat It?, Current Cardiology Reports, 10.1007/s11886-013-0423-x, 15:12, Online publication date: 1-Dec-2013. Sainani K (2013) Interpreting “Null” Results, PM&R, 10.1016/j.pmrj.2013.05.003, 5:6, (520-523), Online publication date: 1-Jun-2013. Morales Vidal S and Ruland S (2013) Platelet Antiaggregants in Stroke Prevention, Neurologic Clinics, 10.1016/j.ncl.2013.03.004, 31:3, (633-657), Online publication date: 1-Aug-2013. Morales-Vidal S, Schneck M, Flaster M and Biller J (2014) Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease, Expert Review of Neurotherapeutics, 10.1586/ern.11.185, 12:2, (179-190), Online publication date: 1-Feb-2012. Broussalis E, Killer M, McCoy M, Harrer A, Trinka E and Kraus J (2012) Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention, Drug Discovery Today, 10.1016/j.drudis.2011.11.005, 17:7-8, (296-309), Online publication date: 1-Apr-2012. Killer M, Trinka E, Kraus J and Broussalis E (2011) Discovery, development and effectiveness of coagulation-inhibiting drugs for stroke therapy, Expert Opinion on Drug Discovery, 10.1517/17460441.2011.563732, 6:4, (353-369), Online publication date: 1-Apr-2011. Conrado D, Gonzalez D and Derendorf H (2010) Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke, Annals of the New York Academy of Sciences, 10.1111/j.1749-6632.2010.05729.x, 1207:1, (134-142), Online publication date: 1-Oct-2010. Lee K, Brown D, Dressler D, Amin A, Jamieson D, Krakow D, Rahman S and Likosky D (2008) Secondary prevention of ischemic stroke: Challenging patient scenarios, Journal of Hospital Medicine, 10.1002/jhm.333, 3:S4, (S20-S28) Leung T, Kwon S and Wong K (2016) Management of Patients with Symptomatic Intracranial Atherosclerosis, International Journal of Stroke, 10.1111/j.1747-4949.2005.00014.x, 1:1, (20-25), Online publication date: 1-Feb-2006. Lutsep H (2006) MATCH Results: Implications for the Internist, The American Journal of Medicine, 10.1016/j.amjmed.2005.10.047, 119:6, (526.e1-526.e7), Online publication date: 1-Jun-2006. Schneck M and Biller J (2014) Antithrombotic therapy for prevention of recurrent stroke in the new millenium, Expert Review of Neurotherapeutics, 10.1586/14737175.4.2.145, 4:2, (145-149), Online publication date: 1-Mar-2004. Connors J (2004) Pharmacologic Agents in Stroke Prevention, Acute Stroke Therapy, and Interventional Procedures, Journal of Vascular and Interventional Radiology, 10.1097/01.RVI.0000112975.88422.5D, 15:1, (S87-S101), Online publication date: 1-Jan-2004. Sudlow C and Warlow C (2004) Long-Term Medical Management of Ischemic Stroke and Transient Ischemic Attack Due to Arterial Disease Stroke, 10.1016/B0-44-306600-0/50066-3, (1129-1150), . (2003) ESPRIT: Safety and Efficacy of Oral Anticoagulation—a Rebuttal, Stroke, 34:10, (e184-e184), Online publication date: 1-Oct-2003. Benesch C (2003) Antithrombotic and thrombolytic therapy for ischemic stroke, Current Atherosclerosis Reports, 10.1007/s11883-003-0049-3, 5:4, (267-275), Online publication date: 1-Jul-2003. Ferro J (2003) Cardioembolic stroke: an update, The Lancet Neurology, 10.1016/S1474-4422(03)00324-7, 2:3, (177-188), Online publication date: 1-Mar-2003. Wang T, Luo J, Wang X, Yang K, Jadhav V, Gao P, Ma Y, Zhao N and Jiao L (2020) Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD013267.pub2 Wang T, Yang K, Wang X, Luo J, Gao P, Ma Y, Jadhav V, Zhao N and Jiao L (2019) Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD013267 Basu-Ray I, Sudhakar D, Schwing G, Monlezun D, Zhang L, Shah S, Pujara D, Ting K, Rafeh N, Ali G, Cassidy M, Ellenbogen K, Levine G, Lam W, Mathuria N, Saeed M, Bunch J, Martin-Schild S, Gold M, Aryana A, Razavi M and Rasekh A (2018) Complex Left Atrial Appendage Morphology Is an Independent Risk Factor for Cryptogenic Ischemic Stroke, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2018.00131, 5 June 2002Vol 33, Issue 6 Advertisement Article InformationMetrics https://doi.org/10.1161/01.STR.0000016922.22707.27PMID: 12053018 Manuscript receivedMarch 5, 2002Manuscript acceptedMarch 18, 2002Originally publishedJune 1, 2002 Keywordsstroke, ischemicclinical trialsaspirinanticoagulantsPDF download Advertisement" @default.
• W2020766596 created "2016-06-24" @default.
• W2020766596 creator A5014800121 @default.
• W2020766596 date "2002-06-01" @default.
• W2020766596 modified "2023-09-24" @default.
• W2020766596 title "Warfarin-Aspirin Recurrent Stroke Study (WARSS) Trial" @default.
• W2020766596 cites W131210426 @default.
• W2020766596 cites W1987467897 @default.
• W2020766596 cites W1995192108 @default.
• W2020766596 cites W2024352468 @default.
• W2020766596 cites W2025849635 @default.
• W2020766596 cites W2027538725 @default.
• W2020766596 cites W2156641763 @default.
• W2020766596 cites W2162638782 @default.
• W2020766596 cites W2340635798 @default.
• W2020766596 cites W4252995664 @default.
• W2020766596 doi "https://doi.org/10.1161/01.str.0000016922.22707.27" @default.
• W2020766596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12053018" @default.
• W2020766596 hasPublicationYear "2002" @default.
• W2020766596 type Work @default.
• W2020766596 sameAs 2020766596 @default.
• W2020766596 citedByCount "39" @default.
• W2020766596 countsByYear W20207665962012 @default.
• W2020766596 countsByYear W20207665962013 @default.
• W2020766596 countsByYear W20207665962015 @default.
• W2020766596 countsByYear W20207665962016 @default.
• W2020766596 countsByYear W20207665962017 @default.
• W2020766596 countsByYear W20207665962018 @default.
• W2020766596 countsByYear W20207665962019 @default.
• W2020766596 countsByYear W20207665962020 @default.
• W2020766596 countsByYear W20207665962023 @default.
• W2020766596 crossrefType "journal-article" @default.
• W2020766596 hasAuthorship W2020766596A5014800121 @default.
• W2020766596 hasBestOaLocation W20207665961 @default.
• W2020766596 hasConcept C126322002 @default.
• W2020766596 hasConcept C127413603 @default.
• W2020766596 hasConcept C168563851 @default.
• W2020766596 hasConcept C2776301958 @default.
• W2020766596 hasConcept C2777628954 @default.
• W2020766596 hasConcept C2779161974 @default.
• W2020766596 hasConcept C2780645631 @default.
• W2020766596 hasConcept C535046627 @default.
• W2020766596 hasConcept C71924100 @default.
• W2020766596 hasConcept C78519656 @default.
• W2020766596 hasConceptScore W2020766596C126322002 @default.
• W2020766596 hasConceptScore W2020766596C127413603 @default.
• W2020766596 hasConceptScore W2020766596C168563851 @default.
• W2020766596 hasConceptScore W2020766596C2776301958 @default.
• W2020766596 hasConceptScore W2020766596C2777628954 @default.
• W2020766596 hasConceptScore W2020766596C2779161974 @default.
• W2020766596 hasConceptScore W2020766596C2780645631 @default.
• W2020766596 hasConceptScore W2020766596C535046627 @default.
• W2020766596 hasConceptScore W2020766596C71924100 @default.
• W2020766596 hasConceptScore W2020766596C78519656 @default.
• W2020766596 hasIssue "6" @default.
• W2020766596 hasLocation W20207665961 @default.
• W2020766596 hasLocation W20207665962 @default.
• W2020766596 hasOpenAccess W2020766596 @default.
• W2020766596 hasPrimaryLocation W20207665961 @default.
• W2020766596 hasRelatedWork W2006713942 @default.
• W2020766596 hasRelatedWork W2114223015 @default.
• W2020766596 hasRelatedWork W2115859112 @default.
• W2020766596 hasRelatedWork W2241853559 @default.
• W2020766596 hasRelatedWork W2351809860 @default.
• W2020766596 hasRelatedWork W2369167285 @default.
• W2020766596 hasRelatedWork W2408189509 @default.
• W2020766596 hasRelatedWork W2415605004 @default.
• W2020766596 hasRelatedWork W3029269458 @default.
• W2020766596 hasRelatedWork W3031140333 @default.
• W2020766596 hasVolume "33" @default.
• W2020766596 isParatext "false" @default.
• W2020766596 isRetracted "false" @default.
• W2020766596 magId "2020766596" @default.
• W2020766596 workType "article" @default.